MentionFox
Home › Executive changes › GENELUX Corp
Leadership changes · GNLX · SEC Form 8-K, Item 5.02

Leadership changes at GENELUX Corp (2026)

Before you join, sell to or invest in GENELUX Corp

MentionFox check on GENELUX Corp: only 1 source on file so far (checked 15 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/genelux

Check GENELUX Corp before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about GENELUX Corp?

Who joined and who left GENELUX Corp (GNLX)? 1 appointment reported on 2026-01-02, each cited to the company's own filing.

Jason Litten was named Chief Medical Officer of GENELUX Corp, effective January 2, 2026. As of November 15, 2026, GENELUX Corp has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 2, 2026, naming 1 appointment (Form 8-K, January 2, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Armistice Capital, LLC also filed stake reports on 120 other companies ↓

Sell to companies like GENELUX Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-01-02

GENELUX Corp reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-02. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as GENELUX Corp files it.

Also on the record for GENELUX Corp

DateRecordFigureOur pageSource
November 4, 2026Stake report, Schedule 13G/A, by Aladar Szalay6.2% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Aladar Szalay8.2% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G, by Armistice Capital, LLC9.99% of the class5%+ stakesSource
July 25, 2025Stake report, Schedule 13G/A, by Aladar Szalay8.4% of the class5%+ stakesSource

Selling to them or working with them? See who runs GENELUX Corp now and the warning signs.

Free to see. No signup.

Keep reading

More on GENELUX Corp and the records around it.

GENELUX Corp elsewhere on the record

Companies that share a holder

Want the whole picture on GENELUX Corp?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on GENELUX Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on GENELUX Corp covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    5 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-01-02InChief Medical Officer2026-01-028-K, 2026-01-02

Who leads GENELUX Corp, as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to GENELUX Corp?

New leaders reset buying decisions — get the Full Report on GENELUX Corp: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch GENELUX Corp

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Medical Officer at GENELUX Corp, with the record behind each one.

Find candidates like Chief Medical Officer at GENELUX Corp

Every change, in the filing's words

Filed 2026-01-02 · 8-K

Appointed: Jason Litten, Chief Medical Officer, effective 2026-01-02

Appointment of Jason Litten, M.D. as Chief Medical Officer On January 2, 2026, the Company announced the appointment of Jason Litten, M.D. as the Company's Chief Medical Officer, effective as of January 2, 2026 (the " Effective Date ").

Also stated in this filing

  • Departure of Principal Officer or Named Executive Officer On December 30, 2025, Paul Scigalla, M.D. resigned as Chief Medical Officer of Genelux Corporation (the "Company"), effective immediately.
  • Dr. Litten, 52, most recently served as the Chief Medical Officer of Chimeric Therapeutics, Ltd. since July 2022.
  • Dr. Litten is an expert in clinical oncology with experience developing numerous therapeutics modalities.
  • Dr. Litten notably developed some of the first CAR-T, TCR and NK cell clinical programs, as well as leading the clinical and preclinical development of numerous therapeutic monoclonal antibodies and orally available cancer medicines.
  • From August 2019 to March 2022, Dr. Litten served as the Chief Medical Officer at Artiva Biotherapeutics, Inc. where he built and led Artiva's clinical and regulatory functions.
  • During his time at Artiva, Dr. Litten contributed to launching two clinical NK cell therapy programs, raising over $200 million in private financing and establishing two foundational corporate partnerships.

Tools for this story

Each opens in a new tab, filled in for GENELUX Corp. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/genelux
Last updated 2026-11-15
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined GENELUX Corp? Leadership changes (2026). MentionFox, 2026-11-15. https://mentionfox.com/executive-changes/genelux